No Survival Benefit for Adjuvant HDI in Single Positive SLN Melanoma

Share this content:
Adjuvant high-dose interferon alfa-2b therapy confers no survival benefit in patients with melanoma and a single positive sentinel lymph node.
Adjuvant high-dose interferon alfa-2b therapy confers no survival benefit in patients with melanoma and a single positive sentinel lymph node.

Adjuvant high-dose interferon alfa-2b therapy (HDI) confers no survival benefit in patients with melanoma and a single positive sentinel lymph node, a study published in the Journal of Clinical Oncology has shown.1

For the Sunbelt Melanoma Trial, researchers sought to evaluate the role of HDI or completion lymph node dissection (CLDN) for patients with melanoma staged by SLN biopsy. Researchers enrolled patients 18 to 70 years with primary cutaneous melanoma at least 1.0 mm in Breslow thickness. All participants underwent SLN biopsy.

Patients were then assigned to receive Protocol A or Protocol B depending on their SLN tumor status. In Protocol A, patients with a single tumor-positive lymph node after SLN biopsy underwent CLND and were randomly assigned to HDI or observation.

In Protocol B, patients with tumor-negative SLN underwent molecular staging as detected by reverse transcriptase polymerase chain reaction (RT-PCR). Those positive by PT-PCR were randomly assigned to CLND, or CLND + HDI, or observation.

RELATED: Indoor Tanning Contributing to Steep Increase in Melanoma Rates Among Women

Results of intention-to-treat analyses after a median follow-up of 71 months showed that there were no significant differences in disease-free survival (HR, 0.82; P = .45) or overall survival (HR, 1.10; P = .68) between the 2 treatment arms in Protocol A. Similarly, there were no significant differences in overall disease-free survival (P = .069) or overall survival (P = .77) across the 3 groups in Protocol B.

When patients who did not receive the assigned treatment were excluded, researchers continued to find no significant differences in disease-free or overall survival in Protocol A or Protocol B.

Reference

  1. McMasters KM, Egger ME, Edwards MJ, et al. Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy [published online ahead of print February 8, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.63.3776.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters